The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review

Simone Cilio; Giulia Briatico; Gabriella Brancaccio; Federico Capone; Matteo Ferro; Ciro Imbimbo; Andrea Salonia; Giuseppe Argenziano; Felice Crocetto

doi:10.1515/jbcpp-2023-0223

Artikel

The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review

Simone Cilio , Giulia Briatico , Gabriella Brancaccio , Federico Capone , Matteo Ferro , Ciro Imbimbo , Andrea Salonia , Giuseppe Argenziano und Felice Crocetto

Veröffentlicht/Copyright: 21. November 2023

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology Band 34 Heft 6

Abstract

Introduction

Phosphodiesterase 5 inhibitors (PDE5-is) are used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the warning association between PDE5-is use and the development of cutaneous melanoma. However, these data are contrasting, thus we aim to summarise evidence regarding this association.

Content

A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed. PubMed, EMBASE, and Cochrane library were queried for all the published studies indexed up to the 26th of May 2023. A combination of keywords related to PDE5-is and melanoma were used. Only original studies based on human subjects in the English language were included in the analysis.

Summary and Outlook

Of 505 articles identified, only eight original articles were considered for further analysis. Overall, five of the selected articles including 657,984 subjects agrees on an increased risk of developing melanoma in PDE5-is users. On the other hand, three original articles based on data regarding 360,915 subjects, disagree with the previous statement declaring any association between PDE5-i use and melanoma. Current literature still reports contrasting data regarding the association between PDE5-is assumption and increased risk of melanoma, but a possible association is described, bringing attention to higher risk melanoma category of patients. More clinical studies are needed to clarify the impact of PDE5-is in the development and progression of melanoma.

Keywords: PDE5-i; melanoma; sildenafil; tadalafil; vardenafil; avanafil

Corresponding author: Giulia Briatico, MD, University of Campania, Dermatology Unit, Via Pansini 5, Ed 9c, Naples, Italy, E-mail: giuliabriatico@gmail.com

Research ethics: Not applicable.
Informed consent: Not applicable.
Author contributions: Conceptualization, S.C., F.C., and G.A.; methodology, S.C., F.C., G.B.; formal analysis, review, S.C., F.C.; investigation, S.C.; data curation, C.C., F.C.; writing—original draft preparation, A.A., S.C.; writing—review and editing, A.S., G.A.; supervision, F.C, G.A. The author(s) have (has) accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: The authors states no conflict of interest.
Research funding: None declared.
Data availability: Data are available in scientific databases.

References

1. Salonia, A, Bettocchi, C, Boeri, L, Capogrosso, P, Carvalho, J, Cilesiz, NC, et al.. European association of urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction. Eur Urol 2021;80:333–57. https://doi.org/10.1016/j.eururo.2021.06.007.Suche in Google Scholar PubMed

2. Giuliano, F, Montorsi, F, Mirone, V, Rossi, D, Sweeney, M. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000;164:708–11. https://doi.org/10.1097/00005392-200009010-00021.Suche in Google Scholar PubMed

3. Capece, M, Montorio, D, Comune, C, Aveta, A, Melchionna, A, Celentano, G, et al.. Retinal and optic disc vascular changes in patients using long-term tadalafil: a prospective non-randomized matched-pair study. Diagn Basel Switz 2021;11:802. https://doi.org/10.3390/diagnostics11050802.Suche in Google Scholar PubMed PubMed Central

4. Giuliano, F, Jackson, G, Montorsi, F, Martin-Morales, A, Raillard, P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64:240–55. https://doi.org/10.1111/j.1742-1241.2009.02254.x.Suche in Google Scholar PubMed PubMed Central

5. Pezone, G, Collà Ruvolo, C, Cilio, S, Fraia, A, Di Mauro, E, Califano, G. The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source. Int J Impot Res 2023.10.1038/s41443-023-00762-wSuche in Google Scholar PubMed

6. Loeb, S, Ventimiglia, E, Salonia, A, Folkvaljon, Y, Stattin, P. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst 2017;109:1–3. https://doi.org/10.1093/jnci/djx086.Suche in Google Scholar PubMed PubMed Central

7. Garbe, C, Keim, U, Eigentler, TK, Amaral, T, Katalinic, A, Holleczek, B, et al.. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol JEADV 2019;33:1272–80. https://doi.org/10.1111/jdv.15322.Suche in Google Scholar PubMed

8. Wu, N, Sun, H, Sun, Q, Zhang, F, Ma, L, Hu, Y, et al.. Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis. BMC Cancer 2023;23:414. https://doi.org/10.1186/s12885-023-10891-6.Suche in Google Scholar PubMed PubMed Central

9. Briatico, G, Mancuso, P, Argenziano, G, Longo, C, Mangone, L, Moscarella, E, et al.. Trends in cutaneous melanoma mortality in Italy from 1982 to 2016. Int J Dermatol 2022;61:1237–44. https://doi.org/10.1111/ijd.16173.Suche in Google Scholar PubMed PubMed Central

10. Huang, F, Santinon, F, Flores González, RE, Del Rincón, SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol 2021;11:756001. https://doi.org/10.3389/fonc.2021.756001.Suche in Google Scholar PubMed PubMed Central

11. Dhayade, S, Kaesler, S, Sinnberg, T, Dobrowinski, H, Peters, S, Naumann, U, et al.. Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth. Cell Rep 2016;14:2599–610. https://doi.org/10.1016/j.celrep.2016.02.028.Suche in Google Scholar PubMed

12. Stone, L. Sexual dysfunction: PDE5i and melanoma-correlation is not causation. Nat Rev Urol 2015;12:418. https://doi.org/10.1038/nrurol.2015.170.Suche in Google Scholar PubMed

13. Crocetto, F, Cuomo, V, Santoro, C, Fiorillo, L, Barone, B, Arcaniolo, D, et al.. New possibilities in heart failure: the effects of tadalafil on diastolic function in patients undergoing robot-assisted radical prostatectomy. Appl Sci 2022;12:5629. https://doi.org/10.3390/app12115629.Suche in Google Scholar

14. Li, WQ, Qureshi, AA, Robinson, KC, Han, J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014;174:964–70. https://doi.org/10.1001/jamainternmed.2014.594.Suche in Google Scholar PubMed PubMed Central

15. Loeb, S, Folkvaljon, Y, Lambe, M, Robinson, D, Garmo, H, Ingvar, C, et al.. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015;313:2449–55. https://doi.org/10.1001/jama.2015.6604.Suche in Google Scholar PubMed

16. Lian, Y, Yin, H, Pollak, MN, Carrier, S, Platt, RW, Suissa, S, et al.. Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol 2016;70:808–15. https://doi.org/10.1016/j.eururo.2016.04.035.Suche in Google Scholar PubMed

17. Matthews, A, Langan, SM, Douglas, IJ, Smeeth, L, Bhaskaran, K. Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 2016;13:e1002037. https://doi.org/10.1371/journal.pmed.1002037.Suche in Google Scholar PubMed PubMed Central

18. Pottegård, A, Schmidt, SAJ, Olesen, AB, Achacoso, N, Van Den Eeden, SK, Hallas, J, et al.. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer 2016;115:895–900. https://doi.org/10.1038/bjc.2016.248.Suche in Google Scholar PubMed PubMed Central

19. Shkolyar, E, Li, S, Tang, J, Eisenberg, ML. Risk of melanoma with phosphodiesterase type 5 inhibitor use among patients with erectile dysfunction, pulmonary hypertension, and lower urinary tract symptoms. J Sex Med 2018;15:982–9. https://doi.org/10.1016/j.jsxm.2018.05.002.Suche in Google Scholar PubMed

20. Wayne, G, Demus, T, Jivanji, D, Atri, E, Herzog, B, Wong, V, et al.. Use of phosphodiesterase-5 inhibitors and the incidence of melanoma. Cancer Epidemiol 2022;81:102251. https://doi.org/10.1016/j.canep.2022.102251.Suche in Google Scholar PubMed

21. Lui, JL, Shaw, NM, Abbasi, B, Hakam, N, Breyer, BN. Adverse reactions of PDE5 inhibitors: an analysis of the World Health Organization pharmacovigilance database. Andrology 2023;11:1408–17. https://doi.org/10.1111/andr.13430.Suche in Google Scholar PubMed

Received: 2023-10-07

Accepted: 2023-10-17

Published Online: 2023-11-21

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/jbcpp-2023-0223

Schlagwörter für diesen Artikel

PDE5-i; melanoma; sildenafil; tadalafil; vardenafil; avanafil